EGFR and lung carcinoma: We showed the effect of afatinib, tyrosine kinase inhibitor for lung cancer with EGFR gene mutation, on PC‐9 cells similarly increased through suppressing the MF characteristics of MRC‐5 by SK‐216 (Figure 4C).